TipRanks
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
US Market
MDNAF
Medicenna Therapeutics Corp
RESEARCH TOOLSreports

Medicenna Therapeutics Corp (MDNAF) Stock Forecast & Price Target

251 Followers
See the Price Targets and Ratings of:

MDNAF Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Medicenna
Therapeutics Corp
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDNAF Stock 12 Month Forecast

There Are No Analyst Ratings for MDNAF In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

MDNAF Financial Forecast

MDNAF Earnings Forecast

Next quarter’s earnings estimate for MDNAF is -$0.03 with a range of -$0.04 to -$0.03. The previous quarter’s EPS was -$0.04. MDNAF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MDNAF has Performed in-line its overall industry.
Next quarter’s earnings estimate for MDNAF is -$0.03 with a range of -$0.04 to -$0.03. The previous quarter’s EPS was -$0.04. MDNAF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MDNAF has Performed in-line its overall industry.
No data currently available

MDNAF Sales Forecast

Next quarter’s sales forecast for MDNAF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MDNAF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MDNAF has Performed in-line its overall industry.
Next quarter’s sales forecast for MDNAF is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MDNAF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MDNAF has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Research Capital Analyst forecast on MDNAF
Andre Uddin
Research Capital
Research Capital
$2.66→$1.14
Buy
224.38%
Upside
Reiterated
06/29/26
Why this analyst just chopped his price target on Medicenna TherapeuticsResearch Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical catalysts, but he has lowered his target after removing MDNA55 partnership assumptions from his valuation.
Bloom Burton Analyst forecast on MDNAF
David Martin PhD
Bloom Burton
Bloom Burton
$2.84
Buy
710.95%
Upside
Reiterated
12/11/25
We have also adjusted our assumption for a $50M near term equity issuance at $2.00 to $1.10. The mixed data at ESMO-IO and resulting adjustments to our model have reduced our target price to C$4.00* (previously US$6.00). Nevertheless, MDNA stock remains a BUY (Speculative) as we continue to believe that MDNA11 is active. The company held $15.7M at September 30, burning approximately $5M/quarter.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Research Capital Analyst forecast on MDNAF
Andre Uddin
Research Capital
Research Capital
$2.66→$1.14
Buy
224.38%
Upside
Reiterated
06/29/26
Why this analyst just chopped his price target on Medicenna TherapeuticsResearch Capital analyst Andre Uddin says Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSX:MDNA) has upcoming clinical catalysts, but he has lowered his target after removing MDNA55 partnership assumptions from his valuation.
Bloom Burton Analyst forecast on MDNAF
David Martin PhD
Bloom Burton
Bloom Burton
$2.84
Buy
710.95%
Upside
Reiterated
12/11/25
We have also adjusted our assumption for a $50M near term equity issuance at $2.00 to $1.10. The mixed data at ESMO-IO and resulting adjustments to our model have reduced our target price to C$4.00* (previously US$6.00). Nevertheless, MDNA stock remains a BUY (Speculative) as we continue to believe that MDNA11 is active. The company held $15.7M at September 30, burning approximately $5M/quarter.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
SIBNSI-Bone
IMUXImmunic
MDWDMediwound
HROWHarrow Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medicenna Therapeutics Corp

3 Months
Andre UddinResearch Capital
Success Rate
6/9 ratings generated profit
67%
Average Return
+51.14%
Copying Andre Uddin's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +51.14% per trade.
1 Year
Andre UddinResearch Capital
Success Rate
7/9 ratings generated profit
78%
Average Return
+180.52%
Copying Andre Uddin's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +180.52% per trade.
2 Years
Andre UddinResearch Capital
Success Rate
5/9 ratings generated profit
56%
Average Return
+82.29%
Copying Andre Uddin's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +82.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDNAF Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
1
1
0
0
Buy
0
0
0
0
0
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
1
1
0
0
In the current month, MDNAF has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MDNAF average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

MDNAF Stock Forecast FAQ

What is MDNAF’s average 12-month price target, according to analysts?
Currently, no data Available
What is MDNAF’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for MDNAF, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is MDNAF a Buy, Sell or Hold?
      Currently, no data Available
      What is Medicenna Therapeutics Corp’s price target?
      Currently, no data Available
      What do analysts say about Medicenna Therapeutics Corp?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of MDNAF?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.